Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 25, Issue 5
  5. Article
Volume 25, Issue 5
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Objective

This study aimed to develop an effective model that identifies high-risk breast cancer (BRCA) patients and optimizes clinical treatments.

Methods

This study includes five public datasets, TCGA-BRCA as the training dataset and other cohorts as the validation datasets. Machine learning algorithms for finding key tumor-associated immune gene pairs (TAIGPs). These TAIGPs were used to construct tumor-associated immune gene pair index (TAIGPI) by multivariate analysis and further validated on the validation datasets. In addition, the differences in clinical prognosis, biological characteristics, and treatment benefits between high and low TAIGPI groups were further analyzed.

Results

The TAIGPI was established by 36 TAIGPs. Better clinical outcomes in the low TAIGPI patients, with consistent results, were also obtained in the validation datasets. The study showed that patients in the low TAIGPI group had a high infiltration of immune cells and low proliferative activity of tumor cells. In contrast, patients in the high TAIGPI group exhibited low infiltration of immune cells and high proliferative activity of tumor cells. In addition, patients in the low TAIGPI group are more likely to benefit from chemotherapy, adjuvant chemotherapy, or immunotherapy.

Conclusions

The TAIGPI can be an effective predictive strategy for the clinical prognosis of breast cancer patients, providing new insights into personalized treatment options for breast cancer patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206336019241119070155
2024-12-17
2025-04-02

  • From This Site

    /content/journals/acamc/10.2174/0118715206336019241119070155
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. MillerK.D. WagleN.S. JemalA. Cancer statistics, 2023.CA Cancer J. Clin.2023731174810.3322/caac.2176336633525
     [Google Scholar]
  2. BursteinH.J. CuriglianoG. ThürlimannB. WeberW.P. PoortmansP. ReganM.M. SennH.J. WinerE.P. GnantM. AebiS. AndréF. BarriosC. BerghJ. BonnefoiH. Bretel MoralesD. BruckerS. BursteinH. CameronD. CardosoF. CareyL. ChuaB. CiruelosE. ColleoniM. CuriglianoG. DelalogeS. DenkertC. DubskyP. EjlertsenB. FitzalF. FrancisP. GalimbertiV. Gamal El Din Mohamed MahmoudH. GarberJ. GnantM. GradisharW. GulluogluB. HarbeckN. HuangC-S. HuoberJ. IlbawiA. JiangZ. JohnstonS. LeeE.S. LoiblS. MorrowM. PartridgeA. PiccartM. PoortmansP. PratA. ReganM. RubioI. RugoH. RutgersE. SedlmayerF. SemiglazovV. SennH-J. ShaoZ. SpanicT. TesarovaP. ThürlimannB. TjulandinS. ToiM. TrudeauM. TurnerN. Vaz LuisI. VialeG. WatanabeT. WeberW.P. WinerE.P. XuB. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Ann. Oncol.202132101216123510.1016/j.annonc.2021.06.02334242744
     [Google Scholar]
  3. AllemaniC. MatsudaT. Di CarloV. HarewoodR. MatzM. NikšićM. BonaventureA. ValkovM. JohnsonC.J. EstèveJ. OgunbiyiO.J. Azevedo e SilvaG. ChenW.Q. EserS. EngholmG. StillerC.A. MonnereauA. WoodsR.R. VisserO. LimG.H. AitkenJ. WeirH.K. ColemanM.P. BouzbidS. Hamdi-ChérifM. ZaidiZ. MeguenniK. RegagbaD. BayoS. Cheick BougadariT. ManrajS.S. BendahhouK. FabowaleA. BradshawD. SomdyalaN.I.M. KumcherI. MorenoF. CalabranoG.H. EspinolaS.B. Carballo QuinteroB. FitaR. DiumenjoM.C. LaspadaW.D. IbañezS.G. LimaC.A. De SouzaP.C.F. Del PinoK. LaporteC. CuradoM.P. de OliveiraJ.C. VenezianoC.L.A. VenezianoD.B. LatorreM.R.D.O. TanakaL.F. RebeloM.S. SantosM.O. GalazJ.C. Aparicio AravenaM. SanhuezaM.J. HerrmannD.A. VargasS. HerreraV.M. UribeC.J. BravoL.E. GarciaL.S. Arias-OrtizN.E. MorantesD. JuradoD.M. Yépez ChamorroM.C. DelgadoS. RamirezM. Galán AlvarezY.H. TorresP. Martínez-ReyesF. JaramilloL. QuintoR. CastilloJ. MendozaM. CuevaP. YépezJ.G. BhakkanB. DeloumeauxJ. JoachimC. MacniJ. CarrilloR. ShalkowK.J. RiveraG.R. PoquiomaE. Tortolero-LunaG. ZavalaD. AlonsoR. BarriosE. EckstrandA. NikiforukC. NoonanG. TurnerD. KumarE. ZhangB. McCrateF.R. RyanS. MacIntyreM. Saint-JacquesN. NishriD.E. McClureC.A. VriendsK.A. KozieS. Stuart-PankoH. FreemanT. GeorgeJ.T. BrockhouseJ.T. O’BrienD.K. HoltA. AlmonL. KwongS. MorrisC. RycroftR. MuellerL. PhillipsC.E. BrownH. CromartieB. SchwartzA.G. VigneauF. LevinG.M. WohlerB. BayaklyR. WardK.C. GomezS.L. McKinleyM. CressR. GreenM.D. MiyagiK. RuppertL.P. LynchC.F. HuangB. TuckerT.C. DeapenD. LiuL. HsiehM.C. WuX.C. SchwennM. GershmanS.T. KnowltonR.C. AlversonG. CopelandG.E. BushhouseS. RogersD.B. Jackson-ThompsonJ. LemonsD. ZimmermanH.J. HoodM. Roberts-JohnsonJ. ReesJ.R. RiddleB. PawlishK.S. StroupA. KeyC. WigginsC. KahnA.R. SchymuraM.J. RadhakrishnanS. RaoC. GiljahnL.K. SlocumbR.M. EspinozaR.E. KhanF. AirdK.G. BeranT. RubertoneJ.J. SlackS.J. GarciaL. RousseauD.L. JanesT.A. SchwartzS.M. BolickS.W. HurleyD.M. WhitesideM.A. Miller-GianturcoP. WilliamsM.A. HergetK. SweeneyC. JohnsonA.T. KeitheriC.M.B. Migliore SantiagoP. BlankenshipS.E. FarleyS. BorchersR. MalickiR. EspinozaJ.R. GrandpreJ. WilsonR. EdwardsB.K. MariottoA. LeiY. WangN. ChenJ.S. ZhouY. HeY.T. SongG.H. GuX.P. MeiD. MuH.J. GeH.M. WuT.H. LiY.Y. ZhaoD.L. JinF. ZhangJ.H. ZhuF.D. JunhuaQ. YangY.L. JiangC.X. BiaoW. WangJ. LiQ.L. YiH. ZhouX. DongJ. LiW. FuF.X. LiuS.Z. ChenJ.G. ZhuJ. LiY.H. LuY.Q. FanM. HuangS.Q. GuoG.P. ZhaolaiH. WeiK. ZengH. DemetriouA.V. MangW.K. NganK.C. KatakiA.C. KrishnatreyaM. JayalekshmiP.A. SebastianP. NandakumarA. MalekzadehR. RoshandelG. Keinan-BokerL. SilvermanB.G. ItoH. NakagawaH. SatoM. ToboriF. NakataI. TeramotoN. HattoriM. KaizakiY. MokiF. SugiyamaH. UtadaM. NishimuraM. YoshidaK. KurosawaK. NemotoY. NarimatsuH. SakaguchiM. KanemuraS. NaitoM. NarisawaR. MiyashiroI. NakataK. SatoS. YoshiiM. OkiI. FukushimaN. ShibataA. IwasaK. OnoC. NimriO. JungK.W. WonY.J. AlawadhiE. ElbasmiA. Ab MananA. AdamF. SanjaajmatsE. TudevU. OchirC. Al KhaterA.M. El MistiriM.M. TeoY.Y. ChiangC.J. LeeW.C. BuasomR. SangrajrangS. Kamsa-ardS. WiangnonS. DaoprasertK. PongnikornD. LeklobA. SangkitipaiboonS. GeaterS.L. SriplungH. CeylanO. KögI. DiricanO. KöseT. GurbuzT. KaraşahinF.E. TurhanD. AktaşU. HalatY. YakutC.I. AltinisikM. CavusogluY. TürkköylüA. ÜçüncüN. HacklM. ZborovskayaA.A. AleinikovaO.V. HenauK. Van EyckenL. ValerianovaZ. YordanovaM.R. ŠekerijaM. DušekL. ZvolskýM. StormH. InnosK. MägiM. MalilaN. SeppäK. JéguJ. VeltenM. CornetE. TroussardX. BouvierA.M. GuizardA.V. BouvierV. LaunoyG. ArveuxP. MaynadiéM. MounierM. WoronoffA.S. DaoulasM. RobaszkiewiczM. ClavelJ. GoujonS. LacourB. BaldiI. PouchieuC. AmadeoB. CoureauG. OrazioS. PreuxP.M. RharbaouiF. MarrerE. TrétarreB. ColonnaM. DelafosseP. LigierK. PlouvierS. Cowppli-BonyA. MoliniéF. BaraS. GanryO. Lapôtre-LedouxB. GrosclaudeP. BossardN. UhryZ. BrayF. PiñerosM. StabenowR. Wilsdorf-KöhlerH. EberleA. LuttmannS. LöhdenI. NenneckeA.L. KieschkeJ. SirriE. EmrichK. ZeissigS.R. HolleczekB. EisemannN. KatalinicA. AsquezR.A. KumarV. PetridouE. ÓlafsdóttirE.J. TryggvadóttirL. Clough-GorrK. WalshP.M. SundsethH. MazzoleniG. VittadelloF. CovielloE. CuccaroF. GalassoR. SampietroG. GiacominA. MagoniM. ArdizzoneA. D’ArgenzioA. CastaingM. GrossoG. LavecchiaA.M. Sutera SardoA. GolaG. GattiL. RicciP. FerrettiS. SerrainoD. ZucchettoA. CelesiaM.V. FilibertiR.A. PannozzoF. MelcarneA. QuartaF. RussoA.G. CarrozziG. CirilliC. Cavalieri d’OroL. RognoniM. FuscoM. VitaleM.F. UsalaM. CusimanoR. MazzuccoW. MichiaraM. SgargiP. BoschettiL. BorcianiE. SeghiniP. MauleM.M. MerlettiF. TuminoR. MancusoP. VicentiniM. CassettiT. SassatelliR. FalciniF. GiorgettiS. CaiazzoA.L. CavalloR. CesaraccioR. PirinoD.R. ContrinoM.L. TisanoF. FanettiA.C. MasperoS. CaroneS. MincuzziA. CandelaG. ScuderiT. GentiliniM.A. PifferS. RossoS. BarchielliA. CaldarellaA. BianconiF. StracciF. ContieroP. TagliabueG. RuggeM. ZorziM. BeggiatoS. BrustolinA. BerrinoF. GattaG. SantM. BuzzoniC. MangoneL. CapocacciaR. De AngelisR. ZanettiR. MaurinaA. PildavaS. LipunovaN. VincerževskienéI. AgiusD. CallejaN. SieslingS. LarønningenS. MøllerB. Dyzmann-SrokaA. TrojanowskiM. GóźdźS. MężykR. MierzwaT. MolongL. RachtanJ. SzewczykS. BłaszczykJ. KępskaK. KościańskaB. TarocińskaK. ZwierkoM. DrosikK. MaksimowiczK.M. Purwin-PorowskaE. RecaE. Wójcik-TomaszewskaJ. TukiendorfA. Grądalska-LampartM. RadziszewskaA.U. GosA. TalerczykM. WyborskaM. DidkowskaJ.A. WojciechowskaU. Bielska-LasotaM. Forjaz de LacerdaG. RegoR.A. BastosJ. SilvaM.A. AntunesL. LaranjaP.J. Mayer-da-SilvaA. MirandaA. BlagaL.M. CozaD. GusenkovaL. LazarevichO. PrudnikovaO. VjushkovD.M. EgorovaA.G. OrlovA.E. KudyakovL.A. PikalovaL.V. AdamcikJ. Safaei DibaC. Primic-ŽakeljM. ZadnikV. LarrañagaN. Lopez de MunainA. HerreraA.A. RedondasR. Marcos-GrageraR. Vilardell GilM.L. MolinaE. Sánchez PerezM.J. Franch SuredaP. RamosM.M. ChirlaqueM.D. NavarroC. ArdanazE.E. GuevaraM.M. Fernández-DelgadoR. Peris-BonetR. CarullaM. GalceranJ. AlberichC. Vicente-RanedaM. KhanS. PetterssonD. DickmanP. AvelinaI. StaehelinK. CameyB. BouchardyC. SchaffarR. FrickH. HerrmannC. BulliardJ.L. Maspoli-ConconiM. KuehniC.E. RedmondS.M. BordoniA. OrtelliL. ChioleroA. KonzelmannI. MatthesK.L. RohrmannS. BroggioJ. RashbassJ. FitzpatrickD. GavinA. ClarkD.I. DeasA.J. HuwsD.W. WhiteC. MontelL. RachetB. TurculetA.D. StephensR. ChalkerE. PhungH. WaltonR. YouH. GuthridgeS. JohnsonF. GordonP. D’OniseK. PriestK. StokesB.C. VennA. FarrugiaH. ThursfieldV. DowlingJ. CurrowD. HendrixJ. LewisC. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet2018391101251023107510.1016/S0140‑6736(17)33326‑329395269
     [Google Scholar]
  4. Ochoa de OlzaM. Navarro RodrigoB. ZimmermannS. CoukosG. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.Lancet Oncol.2020219e419e43010.1016/S1470‑2045(20)30234‑532888471
     [Google Scholar]
  5. BauerK.R. BrownM. CressR.D. PariseC.A. CaggianoV. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype.Cancer200710991721172810.1002/cncr.2261817387718
     [Google Scholar]
  6. CoussensL.M. WerbZ. Inflammation and cancer.Nature2002420691786086710.1038/nature0132212490959
     [Google Scholar]
  7. HuangD. ChenX. ZengX. LaoL. LiJ. XingY. LuY. OuyangQ. ChenJ. YangL. SuF. YaoH. LiuQ. SuS. SongE. Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer.Nat. Immunol.202122786587910.1038/s41590‑021‑00939‑934140678
     [Google Scholar]
  8. XiaL. OyangL. LinJ. TanS. HanY. WuN. YiP. TangL. PanQ. RaoS. LiangJ. TangY. SuM. LuoX. YangY. ShiY. WangH. ZhouY. LiaoQ. The cancer metabolic reprogramming and immune response.Mol. Cancer20212012810.1186/s12943‑021‑01316‑833546704
     [Google Scholar]
  9. BruniD. AngellH.K. GalonJ. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nat. Rev. Cancer2020201166268010.1038/s41568‑020‑0285‑732753728
     [Google Scholar]
  10. GideT.N. QuekC. MenziesA.M. TaskerA.T. ShangP. HolstJ. MadoreJ. LimS.Y. VelickovicR. WongchenkoM. YanY. LoS. CarlinoM.S. GuminskiA. SawR.P.M. PangA. McGuireH.M. PalendiraU. ThompsonJ.F. RizosH. SilvaI.P. BattenM. ScolyerR.A. LongG.V. WilmottJ.S. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy.Cancer Cell2019352238255.e610.1016/j.ccell.2019.01.00330753825
     [Google Scholar]
  11. LiB. CuiY. DiehnM. LiR. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non–small cell lung cancer.JAMA Oncol.20173111529153710.1001/jamaoncol.2017.160928687838
     [Google Scholar]
  12. JiaQ. WuW. WangY. AlexanderP.B. SunC. GongZ. ChengJ.N. SunH. GuanY. XiaX. YangL. YiX. WanY.Y. WangH. HeJ. FutrealP.A. LiQ.J. ZhuB. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.Nat. Commun.201891536110.1038/s41467‑018‑07767‑w30560866
     [Google Scholar]
  13. HoshidaY. BrunetJ.P. TamayoP. GolubT.R. MesirovJ.P. Subclass mapping: identifying common subtypes in independent disease data sets.PLoS One2007211e119510.1371/journal.pone.000119518030330
     [Google Scholar]
  14. TuttA. ToveyH. CheangM.C.U. KernaghanS. KilburnL. GazinskaP. OwenJ. AbrahamJ. BarrettS. Barrett-LeeP. BrownR. ChanS. DowsettM. FlanaganJ.M. FoxL. GrigoriadisA. GutinA. Harper-WynneC. HattonM.Q. HoadleyK.A. ParikhJ. ParkerP. PerouC.M. RoylanceR. ShahV. ShawA. SmithI.E. TimmsK.M. WardleyA.M. WilsonG. GillettC. LanchburyJ.S. AshworthA. RahmanN. HarriesM. EllisP. PinderS.E. BlissJ.M. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat. Med.201824562863710.1038/s41591‑018‑0009‑729713086
     [Google Scholar]
  15. BaselgaJ. CortésJ. KimS.B. ImS.A. HeggR. ImY.H. RomanL. PedriniJ.L. PienkowskiT. KnottA. ClarkE. BenyunesM.C. RossG. SwainS.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N. Engl. J. Med.2012366210911910.1056/NEJMoa111321622149875
     [Google Scholar]
  16. XuB. YanM. MaF. HuX. FengJ. OuyangQ. TongZ. LiH. ZhangQ. SunT. WangX. YinY. ChengY. LiW. GuY. ChenQ. LiuJ. ChengJ. GengC. QinS. WangS. LuJ. ShenK. LiuQ. WangX. WangH. LuoT. YangJ. WuY. YuZ. ZhuX. ChenC. ZouJ. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Oncol.202122335136010.1016/S1470‑2045(20)30702‑633581774
     [Google Scholar]
  17. HolmJ. ErikssonL. PlonerA. ErikssonM. RantalainenM. LiJ. HallP. CzeneK. Assessment of breast cancer risk factors reveals subtype heterogeneity.Cancer Res.201777133708371710.1158/0008‑5472.CAN‑16‑257428512241
     [Google Scholar]
  18. BallotE. GallandL. MananetH. BoidotR. ArnouldL. DesmoulinsI. MayeurD. KaderbhaiC. IlieS. HennequinA. BergeronA. DerangèreV. GhiringhelliF. TruntzerC. LadoireS. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.Breast Cancer Res.20222418010.1186/s13058‑022‑01572‑636401316
     [Google Scholar]
  19. GongY. JiP. YangY.S. XieS. YuT.J. XiaoY. JinM.L. MaD. GuoL.W. PeiY.C. ChaiW.J. LiD.Q. BaiF. BertucciF. HuX. JiangY.Z. ShaoZ.M. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets.Cell Metab.20213315164.e910.1016/j.cmet.2020.10.01233181091
     [Google Scholar]
  20. XuY. DuY. ZhengQ. ZhouT. YeB. WuY. XuQ. MengX. Identification of ferroptosis-related prognostic signature and subtypes related to the immune microenvironment for breast cancer patients receiving neoadjuvant chemotherapy.Front. Immunol.20221389511010.3389/fimmu.2022.89511035603151
     [Google Scholar]
  21. ChenY. LiZ.Y. ZhouG.Q. SunY. An immune-related gene prognostic index for head and neck squamous cell carcinoma.Clin. Cancer Res.202127133034110.1158/1078‑0432.CCR‑20‑216633097495
     [Google Scholar]
  22. GonzalezH. HagerlingC. WerbZ. Roles of the immune system in cancer: from tumor initiation to metastatic progression.Genes Dev.20183219-201267128410.1101/gad.314617.11830275043
     [Google Scholar]
  23. DunnG.P. BruceA.T. IkedaH. OldL.J. SchreiberR.D. Cancer immunoediting: from immunosurveillance to tumor escape.Nat. Immunol.200231199199810.1038/ni1102‑99112407406
     [Google Scholar]
  24. ChenD.S. MellmanI. Oncology meets immunology: the cancer-immunity cycle.Immunity201339111010.1016/j.immuni.2013.07.01223890059
     [Google Scholar]
  25. BayikD. LathiaJ.D. Cancer stem cell–immune cell crosstalk in tumour progression.Nat. Rev. Cancer202121852653610.1038/s41568‑021‑00366‑w34103704
     [Google Scholar]
  26. TessaroF.H.G. KoE.Y. De SimoneM. PirasR. BrozM.T. GoodridgeH.S. BalzerB. ShiaoS.L. GuarnerioJ. Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumor-expressed MIF in shaping macrophage heterogeneity.Cell Rep.2022391211097710.1016/j.celrep.2022.11097735732118
     [Google Scholar]
  27. de BooL. Cimino-MathewsA. LubeckY. DaletzakisA. OpdamM. SandersJ. HooijbergE. van RossumA. LoncovaZ. RiederD. TrajanoskiZ. VolleberghM. Sobral-LeiteM. van de VijverK. BroeksA. van der WielR. van TinterenH. LinnS. HorlingsH.M. KokM. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.Eur. J. Cancer202012724025010.1016/j.ejca.2019.12.00331956037
     [Google Scholar]
  28. PondéN.F. ZardavasD. PiccartM. Progress in adjuvant systemic therapy for breast cancer.Nat. Rev. Clin. Oncol.2019161274410.1038/s41571‑018‑0089‑930206303
     [Google Scholar]
  29. CuriglianoG. BursteinH.J. WinerE.P. GnantM. DubskyP. LoiblS. ColleoniM. ReganM.M. Piccart-GebhartM. SennH.J. ThürlimannB. AndréF. BaselgaJ. BerghJ. BonnefoiH. BruckerS.Y. CardosoF. CareyL. CiruelosE. CuzickJ. DenkertC. Di LeoA. EjlertsenB. FrancisP. GalimbertiV. GarberJ. GulluogluB. GoodwinP. HarbeckN. HayesD.F. HuangC.S. HuoberJ. KhaledH. JassemJ. JiangZ. KarlssonP. MorrowM. OrecchiaR. OsborneK.C. PaganiO. PartridgeA.H. PritchardK. RoJ. RutgersE.J.T. SedlmayerF. SemiglazovV. ShaoZ. SmithI. ToiM. TuttA. VialeG. WatanabeT. WhelanT.J. XuB. De-escalating and escalating treatments for early-stage breast cancer: The St. gallen international expert consensus conference on the primary therapy of early breast cancer 2017.Ann. Oncol.20172881700171210.1093/annonc/mdx30828838210
     [Google Scholar]
  30. KerrA.J. DodwellD. McGaleP. HoltF. DuaneF. MannuG. DarbyS.C. TaylorC.W. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.Cancer Treat. Rev.202210510237510.1016/j.ctrv.2022.10237535367784
     [Google Scholar]
  31. BrufskyA.M. DicklerM.N. Estrogen receptor-positive breast cancer: Exploiting signaling pathways implicated in endocrine resistance.Oncologist201823552853910.1634/theoncologist.2017‑042329352052
     [Google Scholar]
  32. LytleN.K. BarberA.G. ReyaT. Stem cell fate in cancer growth, progression and therapy resistance.Nat. Rev. Cancer2018181166968010.1038/s41568‑018‑0056‑x30228301
     [Google Scholar]
  33. KentL.N. LeoneG. The broken cycle: E2F dysfunction in cancer.Nat. Rev. Cancer201919632633810.1038/s41568‑019‑0143‑731053804
     [Google Scholar]
  34. VaidyanathanS. SalmiT.M. SathiquR.M. McConvilleM.J. CoxA.G. BrownK.K. YAP regulates an SGK1/mTORC1/SREBP-dependent lipogenic program to support proliferation and tissue growth.Dev. Cell2022576719731.e810.1016/j.devcel.2022.02.00435216681
     [Google Scholar]
  35. SchulzeA. OshiM. EndoI. TakabeK. MYC targets scores are associated with cancer aggressiveness and poor survival in ER-positive primary and metastatic breast cancer.Int. J. Mol. Sci.20202121812710.3390/ijms2121812733143224
     [Google Scholar]
  36. O’DonnellJ.S. TengM.W.L. SmythM.J. Cancer immunoediting and resistance to T cell-based immunotherapy.Nat. Rev. Clin. Oncol.201916315116710.1038/s41571‑018‑0142‑830523282
     [Google Scholar]
  37. VeselyM.D. ZhangT. ChenL. Resistance mechanisms to anti-PD cancer immunotherapy.Annu. Rev. Immunol.2022401457410.1146/annurev‑immunol‑070621‑03015535471840
     [Google Scholar]
  38. GalonJ. BruniD. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.Nat. Rev. Drug Discov.201918319721810.1038/s41573‑018‑0007‑y30610226
     [Google Scholar]
  39. ZhangJ. HuangD. SawP.E. SongE. Turning cold tumors hot: From molecular mechanisms to clinical applications.Trends Immunol.202243752354510.1016/j.it.2022.04.01035624021
     [Google Scholar]
  40. KishtonR.J. SukumarM. RestifoN.P. Metabolic regulation of T cell longevity and function in tumor immunotherapy.Cell Metab.20172619410910.1016/j.cmet.2017.06.01628683298
     [Google Scholar]
  41. DaassiD. MahoneyK.M. FreemanG.J. The importance of exosomal PDL1 in tumour immune evasion.Nat. Rev. Immunol.202020420921510.1038/s41577‑019‑0264‑y31965064
     [Google Scholar]
  42. ChenD.S. MellmanI. Elements of cancer immunity and the cancer–immune set point.Nature2017541763732133010.1038/nature2134928102259
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206336019241119070155
Loading
A Novel Effective Models for Identifying BRCA Patients and Optimizing Clinical Treatments
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 357 (2025); https://doi.org/10.2174/0118715206336019241119070155
/content/journals/acamc/10.2174/0118715206336019241119070155
/content/journals/acamc/10.2174/0118715206336019241119070155
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Breast cancer; immune system; machine learning; precise treatment; prognosis; tumor-associated immune gene pairs

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test